Free tool
FAERS Monitor: Airsupra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214070 or its brand name (Airsupra, Albuterol Sulfate, Budesonide). Reports on generic versions are filed under their own applications.
Reports
1,599
Serious
319
20% of reports
Hospitalization
114
Death reported
18
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- device delivery system issue422
- product dose omission issue261
- asthma197
- dyspnoea183
- device malfunction179
- wrong technique in device usage process168
- drug ineffective137
- wrong technique in product usage process134
- incorrect dose administered by device130
- device use issue128
- cough110
- incorrect dose administered95
- drug dose omission by device88
- product use issue84
- device defective66
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 7 |
| 2023 | 14 |
| 2024 | 208 |
| 2025 | 784 |
| 2026 | 581 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,560 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device delivery system issueSignal | 422 | 205.9 | 189.6 | 84,633 |
| device use issueSignal | 128 | 96.9 | 82.1 | 11,981 |
| incorrect dose administered by deviceSignal | 130 | 65.6 | 55.6 | 8,170 |
| device defectiveSignal | 66 | 50.3 | 39.7 | 3,129 |
| wrong technique in device usage processSignal | 168 | 47.5 | 41.1 | 7,587 |
| device malfunctionSignal | 179 | 33.6 | 29.3 | 5,632 |
| asthmaSignal | 197 | 23.0 | 20.1 | 4,132 |
| drug dose omission by deviceSignal | 88 | 14.8 | 12.1 | 1,121 |
| product dose omission issueSignal | 261 | 11.7 | 10.5 | 2,573 |
| wrong technique in product usage processSignal | 134 | 8.7 | 7.4 | 914 |
| product use issueSignal | 84 | 5.9 | 4.8 | 338 |
| incorrect dose administeredSignal | 95 | 5.5 | 4.5 | 347 |
| coughSignal | 110 | 5.2 | 4.3 | 370 |
| dyspnoeaSignal | 183 | 4.3 | 3.7 | 464 |
| drug ineffective | 137 | 1.4 | 1.2 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.